Erlotinib: all 574 studies that test it

Page 1 of 6. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 2
• Epidermal Growth Factor Receptor Inhibition for KeratinopathiesNot yet recruitingNCT06545695Phase 1/2
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingNCT06483555Phase 1/2
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
• A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingNCT05904457Phase 2
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• Erlotinib for Hepatocellular Carcinoma ChemopreventionNot yet recruitingNCT04172779Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaTerminatedNCT03213626Phase 2Results posted
• A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibCompletedNCT03076164Phase 1/2Results posted
• Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerCompletedNCT02961374Phase 2Results posted
• A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02774278Phase 2Results posted
• Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerTerminatedNCT02770014Phase 2Results posted
• A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic CancerCompletedNCT02694536Phase 3Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02507375Phase 1Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsCompletedNCT02450591Not applicableResults posted
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerCompletedNCT02424617Phase 1/2Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverCompletedNCT02273362Phase 1/2Results posted
• Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryTerminatedNCT02169284Phase 2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to ChemotherapyCompletedNCT02013206Phase 2Results posted
• Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese PopulationCompletedNCT02000531Phase 4Results posted
• A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01996332Phase 2Results posted
• A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell TumorsTerminatedNCT01962896Phase 2Results posted
• Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical ResectionCompletedNCT01927744Phase 2Results posted
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT01900652Phase 2Results posted
• Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerCompletedNCT01866410Phase 2Results posted
• Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung CancerTerminatedNCT01857271Phase 2Results posted
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerTerminatedNCT01822496Phase 2Results posted
• Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT01708954Phase 2Results posted
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryCompletedNCT01688973Phase 2Results posted
• A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01667562Phase 3Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.CompletedNCT01652469Phase 3Results posted
• A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4Results posted
• Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal MesotheliomaCompletedNCT01592383Phase 2Results posted
• Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)CompletedNCT01573702Phase 2Results posted
• Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaCompletedNCT01565538Phase 2Results posted
• BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)CompletedNCT01562028Phase 2Results posted
• Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT01557959Phase 2Results posted
• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibCompletedNCT01487265Phase 2Results posted
• Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results posted
• Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01395758Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)CompletedNCT01378962Phase 2Results posted
• GSK1120212 Rollover StudyTerminatedNCT01376310Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor MutationsCompletedNCT01372384Phase 2Results posted
• Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung CancerCompletedNCT01350817Phase 2Results posted
• A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR MutationsCompletedNCT01342965Phase 3Results posted
• A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT01310036Phase 2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT01302808Phase 1Results posted
• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyCompletedNCT01294306Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR MutationsCompletedNCT01287754Phase 4Results posted
• A Safety Study in Participants With Advanced Solid TumorsTerminatedNCT01284335Phase 1Results posted
• A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsCompletedNCT01260181Phase 2Results posted
• Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerCompletedNCT01259089Phase 1/2Results posted
• A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.CompletedNCT01250119Phase 2Results posted
• BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01248247Phase 2Results posted
• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205TerminatedNCT01247922Phase 2Results posted
• AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerCompletedNCT01233687Phase 1/2Results posted
• A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease ProgressionCompletedNCT01230710Phase 4Results posted
• Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...CompletedNCT01229150Phase 2Results posted
• Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01222689Phase 2Results posted
• Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast CancerTerminatedNCT01205685Phase 2Results posted
• CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT01199068Phase 1Results posted
• Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell CarcinomaCompletedNCT01198028Phase 2Results posted
• A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01196078Phase 4Results posted
• Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT01192815Phase 2Results posted
• Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or GefitinibTerminatedNCT01189435Phase 2Results posted
• A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsCompletedNCT01187901Phase 2Results posted
• A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)CompletedNCT01183858Phase 3Results posted
• Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)TerminatedNCT01182350Phase 2Results posted
• Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line TherapyCompletedNCT01180959Phase 2Results posted
• A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line TherapyCompletedNCT01174563Phase 2Results posted
• Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid LeukemiaCompletedNCT01174043Phase 2Results posted
• A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating MutationsCompletedNCT01153984Phase 2Results posted
• A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.CompletedNCT01135498Phase 2Results posted
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompletedNCT01130519Phase 2Results posted
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
• A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic AdenocarcinomaTerminatedNCT01108458Phase 2Results posted
• Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerCompletedNCT01104155Phase 2Results posted
• Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT01093222Phase 2Results posted
• Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT01064479Phase 2Results posted
• Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the SkinTerminatedNCT01059305Phase 2Results posted
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraTerminatedNCT01038856Phase 2Results posted
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaTerminatedNCT01032070Phase 2Results posted
• Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01026844Phase 1Results posted
• Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryCompletedNCT01013649Phase 3Results posted
• Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaTerminatedNCT01009203Phase 2Results posted
• Topotecan With Erlotinib for Topotecan Pretreated Ovarian CancerTerminatedNCT01003938Phase 2Results posted
• Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLCCompletedNCT00997334Phase 2Results posted
• Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate CancerTerminatedNCT00996502Phase 1/2Results posted

← Erlotinib overview